27 periodic reviews. 650+ documents analyzed. One clear view of system health. Periodic reviews are intended to answer a relatively simple question: is this GxP system or piece of computerized equipment still operating in a controlled and appropriately validated or qualified state? Getting to that answer is rarely simple. A reviewer may need to look
Pharma companies cannot rely on standard commercial SaaS contracts alone when regulated systems, GxP data, or AI-enabled workflows are involved. In regulated environments, contracts and SLAs help define operational oversight expectations that support validation, data integrity, cybersecurity, supplier governance, and inspection readiness. Most commercial agreements are designed around uptime and commercial liability. Pharma and biotech
How AI-powered document analytics helps manufacturing teams compare complex documentation, identify process differences, and accelerate technology transfer while keeping GMP decisions under human oversight. Technology Transfer Is Still a Documentation-Intensive Process Successful technology transfer is about far more than moving a manufacturing process from one facility to another. It requires ensuring that manufacturing knowledge is
How Assurea helped a biotechnology company assess and align site vs global QMS following an acquisition using AI-assisted analytics and expert quality review. Project Overview Following the acquisition of a biotechnology company, our client needed to understand how the acquired site’s Quality Management System (QMS) aligned with its global quality framework before beginning integration activities.
Defining intended use is one of the most important steps in validating AI and SaaS tools in regulated pharma and biotech environments. The intended use statement establishes validation scope, testing strategy, risk classification, supplier oversight expectations, and procedural controls. For AI systems, this is often more difficult than traditional software because operational usage can evolve
An AI governance framework for pharma works only when it goes beyond policy. It needs to connect each AI use case to a clear intended use, a defined risk tier, required controls, and ongoing monitoring. That is what makes the framework usable in practice and defensible in audit. If those links are missing, the framework
Turning Supplier Audit Files into Actionable Insights for a Mid-Size Biotech Introduction A mid-size biotech organization with approximately 600 employees and a single GMP manufacturing site faced a common challenge: hundreds of supplier audit reports, self-assessment questionnaires, and CAPA summaries stored across multiple folders, but no easy way to extract trends or prioritize risks. The
Scenario & Background A mid-sized biotech company developing a novel oncology cell therapy was running multiple Phase II trials across different sites. The company’s internal safety team was overwhelmed by the volume of adverse event (AE) reports and needed support in: However, the client did not want a new IT platform or continuous system integration.
In the biotech industry, the integrity of documentation is just as critical as the product itself. Master Batch Records (MBRs) guide the execution of production steps, while Standard Operating Procedures (SOPs) define how those steps should be performed and documented. These two document types are deeply interconnected, and any misalignment between them can lead to
Scenario: A Biotech Company Analyzing 500+ Deviations to Uncover Trends and Gain Cross-Departmental Clarity A mid-sized biotech company had over 500 deviations logged at a single manufacturing site, spread across multiple departments including Quality, Manufacturing, Engineering, and Supply Chain. The data resided in their existing systems (QMS, Excel exports, reports), and they saw an opportunity